Neuraxis EPS

Wat doet Neuraxis? Neuraxis Inc develops neuromodulation therapies for chronic and debilitating conditions in children. Headquartered in Carmel, Indiana, the company employs 17 full-time staff. It completed an IPO on August 9, 2023. The company advances Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, with a pipeline device called B-Stim for functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children. The FDA has reviewed indications including chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome. Neuraxis is een van de meest populaire bedrijven op Eulerpool.